ATOP Trial: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 16 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Feb 2017 Planned End Date changed from 1 Jun 2020 to 1 Jan 2022.
- 03 Feb 2017 Planned primary completion date changed from 1 Jun 2020 to 1 Jan 2022.